Engineered Human Myocardium

Principal Investigator: Prof. Dr. med. Wolfram-Hubertus Zimmermann

Remuscularization of the failing human heart is an overarching research interest of the Zimmermann lab. Engineered heart muscle (EHM) is being developed towards clinical applications in heart failure repair. Multiplexing EHM and their combination with other engineered macro organs for applications in the discovery of regenerative therapies is another goal of the Zimmermann lab. This includes studies of organ-to-organ and cell-to-cell cross talk in health and disease. Human pluripotent stem cell models, tissue engineering, and genetic engineering as well as a systems approach, integrating functional phenotypes with morphology and omics data, may serve to better understand disease mechanisms and develop novel pharmacological interventions.

Projects in the lab are primarily developed based on the intention to treat degenerative diseases in heart and brain.

Fujita and Zimmermann (2017) Clin Pharmacol Ther.
DirectorProf. Dr. med. Wolfram-Hubertus Zimmermann
Prof. Dr. med. Wolfram-Hubertus Zimmermann

contact information


Research Groups

Bergmann Group

Regenerative Pharmacology

Principal Investigator:
Dr. med. et rer. nat. habil. Olaf Bergmann

Lutz Group

G Protein Coupled Receptor Mediated Signaling

Principal Investigator:
Prof. Dr. rer. nat. Susanne Lutz

Meyer Group

Decentralized Laboratory Automation / Extrusion 3D Bioprinting of Human Heart Muscle

Principal Investigator:
Tim Meyer, PhD

Tiburcy Group

Striated Muscle Disease Modeling

Principal Investigator:
PD Dr. med. Malte Tiburcy

Voigt Group

Molecular Pharmacology

Principal Investigator:
Prof. Dr. med. Niels Voigt

Zafeiriou Group

3D Electrically Excitable Cell Networks – Brain and Heart

Principal Investigator:
Dr. rer. nat. Maria-Patapia Zafeiriou

Zelarayan Group

Developmental Pharmacology

Principal Investigator:
Prof. Dr. rer. nat. Laura Zelarayan

Follow us